Matthias Schnell, PhD

Contact Dr. Schnell

1020 Locust Street
Room 309
Philadelphia, PA 19107

(215) 503-4634

Most Recent Peer-reviewed Publications

  1. Ifit2 is a restriction factor in rabies virus pathogenicity
  2. Progress in Ebola Virus Vaccine Development
  3. Inactivated recombinant rabies viruses displaying canine distemper virus glycoproteins induce protective immunity against both pathogens
  4. The final (Oral Ebola) vaccine trial on captive chimpanzees?
  5. Toward an Effective Ebola Virus Vaccine
  6. One-Health: A safe, efficient, dual-use vaccine for humans and animals against middle east respiratory syndrome coronavirus and rabies virus
  7. Keeping it in check: Chronic viral infection and antiviral immunity in the brain
  8. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted with Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models
  9. Everything You Always Wanted to Know about Rabies Virus (But Were Afraid to Ask)
  10. Human polyclonal antibodies produced through DNA vaccination of transchromosomal cattle provide mice with post-exposure protection against lethal zaire and Sudan ebolaviruses
  11. Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics
  12. Rhabdovirus-based vaccine platforms against henipaviruses
  13. Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine
  14. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses
  15. Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs
  16. Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo
  17. Rabies virus replication and pathogenesis
  18. Small-molecule probes targeting the viral PPxY-host nedd4 interface block egress of a broad range of RNA viruses
  19. Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment
  20. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses